Cyclooxygenase-2 in Transitional Cell Carcinoma-A Legitimate Target?

Journal of Urology

Volumn 177, Issue 3, 2007, Pages 818-819

  Adam, Rosalyn ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; BCG VACCINE; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DOXORUBICIN; GEFITINIB; IBUPROFEN; INDOMETACIN; N BUTYL N (4 HYDROXYBUTYL)NITROSAMINE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN G2; ROFECOXIB;

CARDIOTOXICITY; EDITORIAL; ENZYME DEGRADATION; HUMAN; HYPERPLASIA; KIDNEY CARCINOMA; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RNA SPLICING; STOMACH ULCER; URINARY TRACT INFECTION; UROTHELIUM;

CARCINOMA, TRANSITIONAL CELL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; URINARY BLADDER NEOPLASMS;

EID: 33846807865     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.12.004     Document Type: Editorial

References (10)

1. Spektor G., and Fuster V. Drug insight: cyclo-oxygenase 2 inhibitors and cardiovascular risk-where are we now?. Nat Clin Pract Cardiovasc Med 2 (2005) 290
2. Simmons D.L., Botting R.M., and Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 56 (2004) 387
3. Thun M.J., Namboodiri M.M., and Heath Jr. C.W. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325 (1991) 1593
4. Meric J.B., Rottey S., Olaussen K., Soria J.C., Khayat D., Rixe O., et al. Cyclooxygenase-2 as a target for anticancer drug development. Crit Rev Oncol Hematol 59 (2006) 51
5. Okajima E., Denda A., Ozono S., Takahama M., Akai H., Sasaki Y., et al. Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine. Cancer Res 58 (1998) 3028
6. Grubbs C.J., Lubet R.A., Koki A.T., Leahy K.M., Masferrer J.L., Steele V.E., et al. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 60 (2000) 5599
7. Klein R.D., VanPelt C.S., Sabichi A.L., DelaCerda J., Fischer S.M., Furstenberger G., et al. Transitional cell hyperplasia and carcinomas in urinary bladders of transgenic mice with keratin 5 promoter-driven cyclooxygenase-2 overexpression. Cancer Res 65 (2005) 1808
8. Castelao J.E., Yuan J.M., Gago-Dominguez M., Yu M.C., and Ross R.K. Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer 82 (2000) 1364
9. Estrada C.R., Adam R.M., Eaton S.H., Bagli D.J., and Freeman M.R. Inhibition of EGFR signaling abrogates smooth muscle proliferation resulting from sustained distension of the urinary bladder. Lab Invest 86 (2006) 1293
10. Farokhzad O.C., Dimitrakov J.D., Karp J.M., Khademhosseini A., Freeman M.R., and Langer R. Drug delivery systems in urology-getting "smarter". Urology 68 (2006) 463